<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9279">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05701436</url>
  </required_header>
  <id_info>
    <org_study_id>2022-KY-277-01</org_study_id>
    <nct_id>NCT05701436</nct_id>
  </id_info>
  <brief_title>Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial</brief_title>
  <official_title>Applicability of 3D Histoculture Drug Response Assay(3D-HDRA) in Patients With Primary Liver Cancer: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhujiang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhujiang Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Randomized Controlled Trial was to clarity the clinical feasibility of 3D-HDRA results&#xD;
      in guiding the drug use of interventional chemotherapy after primary liver cancer surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Data of Patients who received 3D-HDRA after primary liver cancer radical reaction and&#xD;
      received Transarterial Chemoembolization #will be collected #excluding incomplete data.&#xD;
&#xD;
      The primary endpoint was the one-year disease-free survival(DFS) rate #Secondary endpoint was&#xD;
      the adverse event.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2022</start_date>
  <completion_date type="Anticipated">March 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The test group received postoperative conventional treatment combined with precise transarterial chemoembolization based on 3D-HDRA results, and the control group received postoperative conventional treatment combined with Empirical transarterial chemoembolization.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The one-year DFS rate</measure>
    <time_frame>From the start date of the Treatment until date of the time of 1 year</time_frame>
    <description>The one-year DFS rate is defined as the percentage of participants who have not accrued disease at the time of 1 year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>From the beginning of therapy until the date of death from any cause(max 24 months)</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Liver, Cancer of, Primary Resectable</condition>
  <arm_group>
    <arm_group_label>the test group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The test group received postoperative conventional treatment combined with precise transarterial chemoembolization based on 3D-HDRA results. Precise transarterial chemoembolization at 1-month intervals for 4 months after surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>the control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The control group received postoperative conventional treatment combined with Empirical transarterial chemoembolization. Empirical transarterial chemoembolization at 1-month intervals for 4 months after surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>130 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.</description>
    <arm_group_label>the control group</arm_group_label>
    <arm_group_label>the test group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>20 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.</description>
    <arm_group_label>the control group</arm_group_label>
    <arm_group_label>the test group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lobaplatin</intervention_name>
    <description>50 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.</description>
    <arm_group_label>the control group</arm_group_label>
    <arm_group_label>the test group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>50 mg per square body surface area was used for monthly transhepatic arterial infusions.</description>
    <arm_group_label>the control group</arm_group_label>
    <arm_group_label>the test group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin, Leucovorin, fluorouracil</intervention_name>
    <description>Oxaliplatin(130 mg per square body surface area), Leucovorin(400 mg per square body surface area), and fluorouracil(2800 mg per square body surface area) were used for monthly transhepatic arterial infusions.</description>
    <arm_group_label>the control group</arm_group_label>
    <arm_group_label>the test group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lobaplatin, Raltitrexed</intervention_name>
    <description>Lobaplatin(50 mg per square body surface area) and Raltitrexed(3 mg per square body surface area) were used for monthly transhepatic arterial infusions.</description>
    <arm_group_label>the control group</arm_group_label>
    <arm_group_label>the test group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients voluntarily cooperated with the study and signed an informed consent form.&#xD;
&#xD;
          2. Any gender, age 18 or older, 75 or younger.&#xD;
&#xD;
          3. Patients who need to confirm the maximum tumor load (the maximum diameter of a single&#xD;
             tumor lesion) before performing radical surgery; patients with a confirmed diagnosis&#xD;
             of primary liver cancer after postoperative pathological histological examination.&#xD;
&#xD;
          4. Patients with R0 resection confirmed by imaging and pathology (no residual lesions and&#xD;
             complete tumor resection after radical surgery).&#xD;
&#xD;
          5. Child-Pugh score of 5-7 (A or B), patients with a score of 7 must be free of ascites.&#xD;
&#xD;
          6. ECOG physical fitness status score of 0-1.&#xD;
&#xD;
          7. Women of childbearing age with a negative pregnancy test and willing to use effective&#xD;
             contraception for the duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with recurrent liver cancer.&#xD;
&#xD;
          2. Patients with existing extrahepatic distant metastases (including local lymph node&#xD;
             metastases or distant organ metastases: e.g., lung, brain, bone, etc.) at the time of&#xD;
             diagnosis.&#xD;
&#xD;
          3. Treatment with other experimental drugs or other interventions after radical&#xD;
             resection.&#xD;
&#xD;
          4. Patients with other malignant tumors that have not been cured within 5 years.&#xD;
&#xD;
          5. Patients with non-radical resections (R1 and R2 resections).&#xD;
&#xD;
          6. Patients with residual or recurrent lesions detected on imaging within 1-2 months&#xD;
             after surgery.&#xD;
&#xD;
          7. Patients in whom death occurred within 30 days after surgery.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mingxin Pan, Prof</last_name>
    <role>Study Director</role>
    <affiliation>Study Principal Investigator Southern Medical University, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mingxin Pan, Prof</last_name>
    <phone>18928918216</phone>
    <phone_ext>18928918216</phone_ext>
    <email>pmxwxy@sohu.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhujiang Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mingxin Pan, Prof</last_name>
      <phone>18928918216</phone>
      <email>pmxwxy@sohu.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 18, 2023</study_first_submitted>
  <study_first_submitted_qc>January 18, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2023</study_first_posted>
  <last_update_submitted>March 1, 2023</last_update_submitted>
  <last_update_submitted_qc>March 1, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Raltitrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

